{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T15:02:33Z","timestamp":1785250953912,"version":"3.55.0"},"reference-count":34,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,6]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>The authors conducted a phase II clinical trial of lenalidomide and dexamethasone combination therapy in Japanese elderly patients with newly diagnosed multiple myeloma to evaluate its safety and efficacy and to determine whether safety and efficacy correlate with the plasma concentration of lenalidomide.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>Forty patients received oral lenalidomide on days 1\u201321 of a 28-day cycle in addition to weekly doses of dexamethasone. Plasma concentrations of lenalidomide were measured, and the area under the concentration\u2013time curve from 0 to 24 hours (AUC<jats:sub>0\u201324<\/jats:sub>) of lenalidomide was predicted using a formula the authors previously reported in this journal.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>The median age was 75.5 years. Twenty-one patients had renal impairment severe enough to require dose adjustment of lenalidomide. The median initial doses of lenalidomide and dexamethasone were 12.5 and 20 mg, respectively. The overall response rate was 68.6%, and the 2-year overall survival rate was 88.5%. There was no correlation between the response rate and plasma concentration of lenalidomide. Grade 3\u20134 adverse events (AEs) were observed in 57.5% of patients. The AUC<jats:sub>0\u201324<\/jats:sub> of lenalidomide was significantly higher in patients with grade 3\u20134 AEs than in those who did not suffer from AEs (median = 4852.0 versus 2464.9 ng\u00b7h<jats:sup>\u22121<\/jats:sup>\u00b7mL<jats:sup>\u22121<\/jats:sup>, <jats:italic toggle=\"yes\">P<\/jats:italic> = 0.027). Receiver-operating characteristic curve analysis showed that the AUC<jats:sub>0\u201324<\/jats:sub> of lenalidomide was a good predictor of grade 3\u20134 AEs, with an area under the receiver-operating characteristic curve of 0.758 (95% confidence interval, 0.572\u20130.943, <jats:italic toggle=\"yes\">P<\/jats:italic> = 0.027). The cutoff value for best prediction of grade 3\u20134 AEs was 2613.5 ng\u00b7h<jats:sup>\u22121<\/jats:sup>\u00b7mL<jats:sup>\u22121<\/jats:sup> (sensitivity 86.7%, specificity 54.5%). Multivariate logistic analysis confirmed the significance of this cutoff value.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>These data suggest that overexposure to lenalidomide could contribute to toxicity. Furthermore, the predicted cutoff value of AUC<jats:sub>0\u201324<\/jats:sub> can be clinically used to prevent severe AEs.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/ftd.0000000000000499","type":"journal-article","created":{"date-parts":[[2018,2,28]],"date-time":"2018-02-28T22:22:36Z","timestamp":1519856556000},"page":"301-309","source":"Crossref","is-referenced-by-count":11,"title":["Phase II Clinical Trial of Lenalidomide and Dexamethasone Therapy in Japanese Elderly Patients With Newly Diagnosed Multiple Myeloma to Determine Optimal Plasma Concentration of Lenalidomide"],"prefix":"10.1097","volume":"40","author":[{"given":"Takahiro","family":"Kobayashi","sequence":"first","affiliation":[{"name":"Department of Hematology, Nephrology and Rheumatology, Akita University Graduate School of Medicine; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masatomo","family":"Miura","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Akita University Hospital, Akita, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takenori","family":"Niioka","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Akita University Hospital, Akita, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maiko","family":"Abumiya","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Akita University Hospital, Akita, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fumiko","family":"Ito","sequence":"additional","affiliation":[{"name":"Department of Hematology, Nephrology and Rheumatology, Akita University Graduate School of Medicine; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isuzu","family":"Kobayashi","sequence":"additional","affiliation":[{"name":"Department of Hematology, Nephrology and Rheumatology, Akita University Graduate School of Medicine; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sho","family":"Ikeda","sequence":"additional","affiliation":[{"name":"Department of Hematology, Nephrology and Rheumatology, Akita University Graduate School of Medicine; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoko","family":"Yoshioka","sequence":"additional","affiliation":[{"name":"Department of Hematology, Nephrology and Rheumatology, Akita University Graduate School of Medicine; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshihiro","family":"Kameoka","sequence":"additional","affiliation":[{"name":"Department of Hematology, Nephrology and Rheumatology, Akita University Graduate School of Medicine; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoto","family":"Takahashi","sequence":"additional","affiliation":[{"name":"Department of Hematology, Nephrology and Rheumatology, Akita University Graduate School of Medicine; and"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20230814","doi-asserted-by":"crossref","first-page":"225","DOI":"10.4065\/mcp.2009.0426","article-title":"Patterns of multiple myeloma during the past 5 decades: stable incidence rates for all age groups in the population but rapidly changing age distribution in the clinic","volume":"85","author":"Turesson","year":"2010","journal-title":"Mayo Clin Proc."},{"key":"R2-20230814","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1016\/S1470-2045(14)70282-7","article-title":"Survival for haematological malignancies in Europe between 1997 and 2008 by region and age: results of EUROCARE-5, a population-based study","volume":"15","author":"Sant","year":"2014","journal-title":"Lancet Oncol."},{"key":"R3-20230814","doi-asserted-by":"crossref","first-page":"4519","DOI":"10.1182\/blood-2011-06-358812","article-title":"Personalized therapy in multiple myeloma according to patient age and vulnerability: a report of the European Myeloma Network (EMN)","volume":"118","author":"Palumbo","year":"2011","journal-title":"Blood."},{"key":"R4-20230814","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1111\/bjh.12465","article-title":"Survival of multiple myeloma patients in the era of novel therapies confirms the improvement in patients younger than 75 years: a population-based analysis","volume":"163","author":"Pozzi","year":"2013","journal-title":"Br J Haematol."},{"key":"R5-20230814","doi-asserted-by":"crossref","first-page":"980","DOI":"10.3324\/haematol.2012.075051","article-title":"Age and organ damage correlate with poor survival in myeloma patients: meta-analysis of 1435 individual patient data from 4 randomized trials","volume":"98","author":"Bringhen","year":"2013","journal-title":"Haematologica."},{"key":"R6-20230814","doi-asserted-by":"crossref","first-page":"4976","DOI":"10.1200\/JCO.2010.30.8791","article-title":"Renal impairment in patients with multiple myeloma: a consensus statement on behalf of the International Myeloma Working Group","volume":"28","author":"Dimopoulos","year":"2010","journal-title":"J Clin Oncol."},{"key":"R7-20230814","doi-asserted-by":"crossref","first-page":"21","DOI":"10.4065\/78.1.21","article-title":"Review of 1027 patients with newly diagnosed multiple myeloma","volume":"78","author":"Kyle","year":"2003","journal-title":"Mayo Clin Proc."},{"key":"R8-20230814","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/S0268-960X(99)90014-0","article-title":"Renal failure and multiple myeloma: pathogenesis and treatment of renal failure and management of underlying myeloma","volume":"13","author":"Clark","year":"1999","journal-title":"Blood Rev."},{"key":"R9-20230814","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1038\/leu.2008.131","article-title":"Pathogenesis and treatment of renal failure in multiple myeloma","volume":"22","author":"Dimopoulos","year":"2008","journal-title":"Leukemia."},{"key":"R10-20230814","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1034\/j.1600-0609.2000.90221.x","article-title":"Renal failure in multiple myeloma: reversibility and impact on the prognosis. Nordic Myeloma Study Group","volume":"65","author":"Knudsen","year":"2000","journal-title":"Eur J Haematol."},{"key":"R11-20230814","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1093\/annonc\/mdt483","article-title":"Significant improvement in the survival of patients with multiple myeloma presenting with severe renal impairment after the introduction of novel agents","volume":"25","author":"Dimopoulos","year":"2014","journal-title":"Ann Oncol."},{"key":"R12-20230814","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1056\/NEJMoa070594","article-title":"Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma","volume":"357","author":"Dimopoulos","year":"2007","journal-title":"N Engl J Med."},{"key":"R13-20230814","doi-asserted-by":"crossref","first-page":"3609","DOI":"10.1200\/JCO.2016.66.7295","article-title":"Updated outcomes and impact of age with lenalidomide and low-dose dexamethasone or melphalan, prednisone, and thalidomide in the randomized, phase III FIRST trial","volume":"34","author":"Hulin","year":"2016","journal-title":"J Clin Oncol."},{"key":"R14-20230814","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1111\/cas.12916","article-title":"Lenalidomide and low-dose dexamethasone in Japanese patients with newly diagnosed multiple myeloma: a phase II study","volume":"107","author":"Suzuki","year":"2016","journal-title":"Cancer Sci."},{"key":"R15-20230814","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1111\/j.1365-2141.2007.06698.x","article-title":"Lenalidomide-induced myelosuppression is associated with renal dysfunction: adverse events evaluation of treatment-naive patients undergoing front-line lenalidomide and dexamethasone therapy","volume":"138","author":"Niesvizky","year":"2007","journal-title":"Br J Haematol."},{"key":"R16-20230814","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1177\/0091270007309563","article-title":"Pharmacokinetics of lenalidomide in subjects with various degrees of renal impairment and in subjects on hemodialysis","volume":"47","author":"Chen","year":"2007","journal-title":"J Clin Pharmacol."},{"key":"R17-20230814","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1002\/ajh.22260","article-title":"Drug interaction between lenalidomide and itraconazole","volume":"87","author":"Takahashi","year":"2012","journal-title":"Am J Hematol."},{"key":"R18-20230814","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1038\/leu.2011.3","article-title":"Optimizing the use of lenalidomide in relapsed or refractory multiple myeloma: consensus statement","volume":"25","author":"Dimopoulos","year":"2011","journal-title":"Leukemia."},{"key":"R19-20230814","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1007\/s40262-016-0432-1","article-title":"Clinical pharmacokinetics and pharmacodynamics of lenalidomide","volume":"56","author":"Chen","year":"2017","journal-title":"Clin Pharmacokinet."},{"key":"R20-20230814","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/s00280-016-3068-9","article-title":"Pharmacokinetics, safety, and efficacy of lenalidomide plus dexamethasone in patients with multiple myeloma and renal impairment","volume":"78","author":"Bridoux","year":"2016","journal-title":"Cancer Chemother Pharmacol."},{"key":"R21-20230814","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1046\/j.1365-2141.2003.04355.x","article-title":"Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group","volume":"121","year":"2003","journal-title":"Br J Haematol."},{"key":"R22-20230814","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1038\/sj.leu.2404284","article-title":"International uniform response criteria for multiple myeloma","volume":"20","author":"Durie","year":"2006","journal-title":"Leukemia."},{"key":"R23-20230814","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1097\/FTD.0000000000000034","article-title":"A limited sampling model to estimate exposure to lenalidomide in multiple myeloma patients","volume":"36","author":"Shida","year":"2014","journal-title":"Ther Drug Monit."},{"key":"R24-20230814","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/bmt.2012.244","article-title":"Investigation of the freely available easy-to-use software \u201cEZR\u201d for medical statistics","volume":"48","author":"Kanda","year":"2013","journal-title":"Bone Marrow Transpl."},{"key":"R25-20230814","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1111\/j.1651-2227.2006.00178.x","article-title":"Understanding diagnostic tests 3: receiver operating characteristic curves","volume":"96","author":"Akobeng","year":"2007","journal-title":"Acta Paediatr."},{"key":"R26-20230814","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1056\/NEJMoa1402551","article-title":"Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma","volume":"371","author":"Benboubker","year":"2014","journal-title":"N Engl J Med."},{"key":"R27-20230814","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1111\/bcpt.12081","article-title":"Lenalidomide at therapeutic and supratherapeutic doses does not prolong QTc intervals in the thorough QTc study conducted in healthy men","volume":"113","author":"Chen","year":"2013","journal-title":"Basic Clin Pharmacol Toxicol."},{"key":"R28-20230814","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1007\/s00280-012-1966-z","article-title":"Single-dose pharmacokinetics of lenalidomide in healthy volunteers: dose proportionality, food effect, and racial sensitivity","volume":"70","author":"Chen","year":"2012","journal-title":"Cancer Chemother Pharmacol."},{"key":"R29-20230814","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1007\/s00277-016-2662-6","article-title":"Lenalidomide is effective and safe for the treatment of patients with relapsed multiple myeloma and very severe renal impairment","volume":"95","author":"Joao","year":"2016","journal-title":"Ann Hematol."},{"key":"R30-20230814","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1111\/bjh.12805","article-title":"The impact of intra-clonal heterogeneity on the treatment of multiple myeloma","volume":"165","author":"Brioli","year":"2014","journal-title":"Br J Haematol."},{"key":"R31-20230814","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1056\/NEJMoa1505654","article-title":"Elotuzumab therapy for relapsed or refractory multiple myeloma","volume":"373","author":"Lonial","year":"2015","journal-title":"N Engl J Med."},{"key":"R32-20230814","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1056\/NEJMoa1516282","article-title":"Oral ixazomib, lenalidomide, and dexamethasone for multiple myeloma","volume":"374","author":"Moreau","year":"2016","journal-title":"N Engl J Med."},{"key":"R33-20230814","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1056\/NEJMoa1411321","article-title":"Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma","volume":"372","author":"Stewart","year":"2015","journal-title":"N Engl J Med."},{"key":"R34-20230814","doi-asserted-by":"crossref","first-page":"3165","DOI":"10.1182\/blood-2016-03-705319","article-title":"Minimal residual disease monitoring and immune profiling in multiple myeloma in elderly patients","volume":"127","author":"Paiva","year":"2016","journal-title":"Blood."}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00007691-201806000-00003","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,14]],"date-time":"2023-08-14T22:07:24Z","timestamp":1692050844000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00007691-201806000-00003"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6]]},"references-count":34,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0000000000000499","relation":{},"ISSN":["0163-4356"],"issn-type":[{"value":"0163-4356","type":"print"}],"subject":[],"published":{"date-parts":[[2018,6]]}}}